Advances in™ Sickle Cell Disease: Assessing the Impact of Emerging Agents
September 30, 2019
September 30, 2020
Scroll to the Bottom of this Information to Begin this Course
This activity is provided by Physicians’ Education Resource®, LLC.
Supported by an educational grant from Novartis Pharmaceuticals Corporation.
- Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)™
All other health care professionals completing this course will be issued a statement of participation.
This online educational activity is directed toward emergency medicine physicians, hospitalists, hematologists, nurse practitioners, physician assistants, nurses, and other health care professionals who would be involved in the diagnosis and management of SCD.
Sickle cell disease (SCD) is a continually increasing health problem, with approximately 300,000 individuals born annually worldwide with this genetic disease. A defect in the HBB gene on chromosome 11 results in the production of a form of hemoglobin that is less soluble than normal fetal or adult hemoglobin. Lifelong complications resulting from this mutation include anemia, infections, stroke, tissue damage, organ failure, intense painful episodes, and a shorter life expectancy. The intensive treatment needs and unpredictable, debilitating symptoms of people with SCD impose limitations on education, careers, and overall quality of life. Although hematopoietic stem cell transplantation can cure SCD, it is not feasible for most patients. However, new therapies in clinical trials offer targeted, pathophysiologic approaches to improve the quality and duration of life for people with SCD.
Advances in™ Sickle Cell Disease: Assessing the Impact of Emerging Agents will help clinicians apply a guideline-based approach for management of acute and chronic pain as well as the complications of SCD through a series of video interviews with 2 experts in SCD. The essentials of preventive care, multidisciplinary communication of treatment plans, importance of patient education, and efficacy and safety of emerging agents for treatment of SCD will be discussed.
Benefits of Participating
- Increase knowledge and competence regarding preventive health maintenance and pain treatment care plans for people with SCD
- Learn strategies to effectively manage acute pain episodes in the emergency department
- Build confidence in your knowledge of how to optimally treat various complications of SCD
- Understand the pathophysiologic approaches of emerging and investigative agents
Upon completion of this activity, participants should be able to:
- Summarize current guidelines for management of pain and complications due to SCD in affected patients.
- Evaluate the efficacy and tolerability of agents for SCD being investigated in clinical trials.
Jason W. Wilson, MD, MA, FACEP, FAAEM
Medical Director, Clinical Decision Unit
Associate Medical Director, Adult Education
Research Director, Emergency Medicine
Associate Professor, Division of Emergency Medicine
Department of Internal Medicine
Morsani College of Medicine at the University of South Florida
Tampa General Hospital
Matthew M. Heeney, MD
Associate Chief, Hematology
Director, Sickle Cell Program
Boston Children’s Hospital
Assistant Professor, Pediatrics
Harvard Medical School
Physician Accreditation Statement
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians
Physician Credit Designation
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures of Conflicts of Interest
Jason W. Wilson, MD, MA, FACEP, FAAEM
- Grant/Research Support: Gilead, Boehringer Ingelheim, Portola
- Consultant: Janssen, Pfizer, Gilead, Portola; Speakers Bureau: Janssen, Pfizer, Gilead, Portola.
Matthew M. Heeney, MD
- Grant/Research Support: AstraZeneca, Sancilio/Micelle BioPharma, Pfizer, Novartis, Ironwood/Cyclerion, Intrinsic LifeSciences
- Consultant: AstraZeneca, Sancilio/Micelle Biopharma, Novartis
- Other: Advisory Board: AstraZeneca, Sancilio/Micella Biopharma, Novartis
- Data Safety Monitoring Board: Vertex/CRISPR Therapeutics.
PER® uses a blinded peer review process. The peer reviewer discloses the following: Peer reviewer has no relevant financial relationships with commercial interests to disclose.
The staff of Physicians' Education Resource®, LLC, (PER®) have no relevant financial relationships with commercial interests to disclose.
Method of Participation
Instructions for This Activity and Receiving Credit
- You will need to log in to participate in the activity.
- Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review audio files/content until you finish the presentation.
- At the end of the activity, educational content/audio files will be available for your reference.
- In order to receive a CME/CE certificate, you must complete the activity.
- Complete the Posttest and pass with a score of 70% or higher, complete the Evaluation, and then click on “Request for Credit.” You may immediately download a CME/CE certificate upon completion of these steps.
Course Viewing Requirements
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.
Disclosure Policy and Resolution of Conflicts of Interest (COI)
As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME/CE activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME/CE activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.
Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical and nursing education purposes only and is not meant to substitute for the independent clinical judgment of a physician and nurse relative to diagnostic or treatment options for a specific patient’s medical condition.
The opinions expressed in the content are solely those of the individual faculty members, and do not reflect those of PER® or the company that provided commercial support for this program.